Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,408.50
(
-1.24%
)
US TECH 100
28,244.40
(
-1.90%
)
Dow Jones
49,526.17
(
-1.07%
)
Brent Oil
106.70
(
0.00%
)
Bitcoin
77,884.26
(
-0.34%
)
News Focus
News Focus
Post# of 257580
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122988
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: dewophile post# 89527

Thursday, 02/17/2011 6:52:29 PM

Thursday, February 17, 2011 6:52:29 PM

Post# of 257580
Conatus starts phase-2b trial in HCV null-responders:

http://finance.yahoo.com/news/Conatus-Pharmaceuticals-prnews-802390242.html?x=0&.v=1

This is possibly the oddest HCV program I know of. Conatus, who is private, seems to not quite be sure if CTS-1027 is an antiviral drug or something else. For background, please see the embedded links in #msg-46034554.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today